JPWO2020061430A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020061430A5 JPWO2020061430A5 JP2021516652A JP2021516652A JPWO2020061430A5 JP WO2020061430 A5 JPWO2020061430 A5 JP WO2020061430A5 JP 2021516652 A JP2021516652 A JP 2021516652A JP 2021516652 A JP2021516652 A JP 2021516652A JP WO2020061430 A5 JPWO2020061430 A5 JP WO2020061430A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cationic polymer
- composition according
- polymer
- direct bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000007894 caplet Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 210000001198 duodenum Anatomy 0.000 claims description 5
- 239000002662 enteric coated tablet Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010033307 Overweight Diseases 0.000 claims description 2
- 208000001280 Prediabetic State Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920006317 cationic polymer Polymers 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- -1 lactose or sucrose Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024073800A JP2024096280A (ja) | 2018-09-20 | 2024-04-30 | ボロン酸ポリマーおよび使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734054P | 2018-09-20 | 2018-09-20 | |
| US62/734,054 | 2018-09-20 | ||
| PCT/US2019/052110 WO2020061430A1 (en) | 2018-09-20 | 2019-09-20 | Boronic acid polymers and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024073800A Division JP2024096280A (ja) | 2018-09-20 | 2024-04-30 | ボロン酸ポリマーおよび使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501483A JP2022501483A (ja) | 2022-01-06 |
| JPWO2020061430A5 true JPWO2020061430A5 (https=) | 2024-05-15 |
| JP2022501483A5 JP2022501483A5 (https=) | 2024-05-15 |
| JP7539374B2 JP7539374B2 (ja) | 2024-08-23 |
Family
ID=69887916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516652A Active JP7539374B2 (ja) | 2018-09-20 | 2019-09-20 | ボロン酸ポリマーおよび使用方法 |
| JP2024073800A Pending JP2024096280A (ja) | 2018-09-20 | 2024-04-30 | ボロン酸ポリマーおよび使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024073800A Pending JP2024096280A (ja) | 2018-09-20 | 2024-04-30 | ボロン酸ポリマーおよび使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210403625A1 (https=) |
| EP (1) | EP3852768A4 (https=) |
| JP (2) | JP7539374B2 (https=) |
| WO (1) | WO2020061430A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220233583A1 (en) * | 2019-06-06 | 2022-07-28 | Shanghai Jiaotong University | Method for treating or preventing saccharide-related diseases or disorders |
| WO2021055759A1 (en) | 2019-09-20 | 2021-03-25 | Glyscend, Inc. | Substituted phenyl boronic acid containing polymers and methods of use |
| CN116333197A (zh) * | 2023-04-12 | 2023-06-27 | 厦门君德医药科技有限公司 | 胃肠道粘膜性聚合物、组合物及制备方法和应用 |
| WO2026053928A1 (ja) * | 2024-09-03 | 2026-03-12 | 株式会社シード | 重合性ボロン酸化合物及び重合性カチオン性化合物を構成単位として含む高分子化合物及びその利用 |
| CN120005104B (zh) * | 2025-01-23 | 2025-10-31 | 武汉理工大学 | 一种pH响应型聚氨酯纳米材料、药物递送系统及制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05310844A (ja) * | 1992-05-08 | 1993-11-22 | Nippon Oil & Fats Co Ltd | フェニルボロン酸基含有重合体 |
| JPH07304971A (ja) * | 1994-05-09 | 1995-11-21 | Nippon Oil & Fats Co Ltd | 糖応答性高分子材料 |
| JP3867400B2 (ja) * | 1998-05-08 | 2007-01-10 | 日本油脂株式会社 | ボロン酸基含有単量体およびその重合体 |
| US7041280B2 (en) * | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
| US7662360B2 (en) * | 2002-07-22 | 2010-02-16 | Psimei Pharmaceuticals Plc | Conjugates of N-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds |
| AU2003291567A1 (en) * | 2002-11-19 | 2004-06-15 | Genzyme Corporation | Polymeric boronic acid derivatives as lipase inhibitors |
| EP2226075A1 (en) * | 2007-11-22 | 2010-09-08 | The University of Tokyo | Material for preventing tissue adhesion and material for preventing joint contracture |
| WO2011106542A2 (en) * | 2010-02-24 | 2011-09-01 | Relypsa, Inc. | Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants |
| US9730637B2 (en) * | 2011-08-19 | 2017-08-15 | The Regents Of The University Of California | Layered particles for retrieving DNA released from cells from a gastrointestinal tract sample and methods for making and using them |
| JP6784352B2 (ja) * | 2015-05-11 | 2020-11-11 | 国立大学法人 東京医科歯科大学 | インスリン送達用デバイス |
| WO2017024237A1 (en) * | 2015-08-06 | 2017-02-09 | The Johns Hopkins University | Composition and method for treatment of metabolic disorders |
-
2019
- 2019-09-20 EP EP19862403.3A patent/EP3852768A4/en active Pending
- 2019-09-20 JP JP2021516652A patent/JP7539374B2/ja active Active
- 2019-09-20 US US17/277,702 patent/US20210403625A1/en not_active Abandoned
- 2019-09-20 WO PCT/US2019/052110 patent/WO2020061430A1/en not_active Ceased
-
2024
- 2024-04-30 JP JP2024073800A patent/JP2024096280A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11426388B2 (en) | Controlled release pharmaceutical formulations of nitazoxanide | |
| KR100572785B1 (ko) | 신규한 약학 조성물 | |
| US9439866B2 (en) | Trazodone composition for once a day administration | |
| KR102105217B1 (ko) | 다이메틸 푸마레이트를 함유하는 약학 조성물 | |
| JP7697885B2 (ja) | 化合物の製剤およびそれらの使用 | |
| US20110015205A1 (en) | Trazodone Composition for Once a Day Administration | |
| HUP0201450A2 (hu) | Fokozott biológiai hozzáférhetőségű szilárdfázisú celecoxib forma, ezt tartalmazó gyógyászati készítmények és előállításuk | |
| CN102369000A (zh) | 包含一种或多种富马酸酯的药用组合物 | |
| TW201605435A (zh) | 包含反丁烯二酸二甲酯之醫藥組成物 | |
| AU2013237881B2 (en) | Dosage forms of halofuginone and methods of use | |
| WO1992021345A1 (en) | Composition, method and kit for potentiating antitumor activity and for curing tumor | |
| JP4632204B2 (ja) | 下痢型過敏性腸症候群治療剤 | |
| WO2000000187A1 (fr) | Compositions medicinales destinees au traitement de l'insuffisance d'evacuation | |
| CN116368141B (zh) | 噻二唑酮衍生物及其作为ampk激动剂用于治疗糖尿病和相关疾病的用途 | |
| JPWO2020061430A5 (https=) | ||
| CN100372533C (zh) | 腹泻为主大肠激惹综合征的治疗制剂 | |
| WO1996011682A1 (en) | Preventive and remedy for type i allergic diseases | |
| TWI439269B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途 | |
| CZ20032256A3 (en) | Medicinal compositions comprising diclofenac and ornoprostil | |
| WO1996030016A2 (en) | Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases | |
| EP4633620A1 (en) | Stat3 inhibitors for use in the treatment of non-viral liver cancer | |
| JPWO2021055759A5 (https=) | ||
| US20250262165A1 (en) | Compositions and methods for treating bile acid malabsorption | |
| WO2025163534A1 (en) | Crystal form of a peptide inhibitor of interleukin-23 receptor | |
| KR20260037952A (ko) | 육산화사비소를 유효성분으로 포함하는 대사이상 관련 지방간질환 치료 또는 예방용 조성물 |